TY - JOUR
T1 - The 3A3B score
T2 - The simple risk score for heart failure with preserved ejection fraction - A report from the CHART-2 Study
AU - Kasahara, Shintaro
AU - Sakata, Yasuhiko
AU - Nochioka, Kotaro
AU - Tay, Wan Ting
AU - Claggett, Brian Lee
AU - Abe, Ruri
AU - Oikawa, Takuya
AU - Sato, Masayuki
AU - Aoyanagi, Hajime
AU - Miura, Masanobu
AU - Shiroto, Takashi
AU - Takahashi, Jun
AU - Sugimura, Koichiro
AU - Teng, Tiew Hwa Katherine
AU - Miyata, Satoshi
AU - Shimokawa, Hiroaki
N1 - Funding Information:
The Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) study is supported by grants from National Medical Research Council of Singapore, Agency for Science, Technology and Research Biomedical Research Council Asian Network for Translational Research and Cardiovascular Trials program, Boston Scientific Investigator Sponsored Research Program, and Bayer .
Funding Information:
The Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) study is supported by grants from National Medical Research Council of Singapore, Agency for Science, Technology and Research Biomedical Research Council Asian Network for Translational Research and Cardiovascular Trials program, Boston Scientific Investigator Sponsored Research Program, and Bayer.
Funding Information:
The TOPCAT trial is supported by a contract from the National Heart, Lung, and Blood Institute, National Institutes of Health ( HHSN268200425207C ).
Funding Information:
Acknowledgement of grant support: The CHART-2 Study is supported in part by the Grants-in Aid from the Japanese Ministry of Health, Labour and Welfare and the Japanese Ministry of Education, Culture, Sports, Science and Technology and the Japan Agency for Medical Research and Development (15ek0210043h0001, 16ek0210056h0001, 16ek0210043h0002), Tokyo, Japan.The TOPCAT trial is supported by a contract from the National Heart, Lung, and Blood Institute, National Institutes of Health (HHSN268200425207C).The Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) study is supported by grants from National Medical Research Council of Singapore, Agency for Science, Technology and Research Biomedical Research Council Asian Network for Translational Research and Cardiovascular Trials program, Boston Scientific Investigator Sponsored Research Program, and Bayer.? Acknowledgement of grant support: The CHART-2 Study is supported in part by the Grants-in Aid from the Japanese Ministry of Health, Labour and Welfare and the Japanese Ministry of Education, Culture, Sports, Science and Technology and the Japan Agency for Medical Research and Development (15ek0210043h0001 16ek0210056h0001 16ek0210043h0002), Tokyo, Japan. The TOPCAT trial is supported by a contract from the National Heart, Lung, and Blood Institute, National Institutes of Health (HHSN268200425207C). The Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) study is supported by grants from National Medical Research Council of Singapore, Agency for Science, Technology and Research Biomedical Research Council Asian Network for Translational Research and Cardiovascular Trials program, Boston Scientific Investigator Sponsored Research Program, and Bayer. We thank the CHART-2 investigators, all the members of the Tohoku Heart Failure Association, and the staff of the Departments of Cardiovascular Medicine and Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, for their contributions (Supplementary file). We also thank the TOPCAT investigators, particularly Dr. Mark A. Pfeffer, and the ASIAN-HF investigators, particularly Dr. Carolyn S.P. Lam, for their significant contributions (Supplementary file). The Department of Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, is supported in part by unrestricted research grants from Daiichi Sankyo (Tokyo, Japan), Bayer Yakuhin (Osaka, Japan), Kyowa Hakko Kirin (Tokyo, Japan), Novartis Pharma (Tokyo, Japan), Dainippon Sumitomo Pharma (Osaka, Japan), Astellas Pharma (Tokyo, Japan), AstraZeneca (Osaka, Japan), Chugai Pharmaceutical (Tokyo, Japan), GlaxoSmithKline (Tokyo, Japan), Kowa Pharmaceutical (Tokyo, Japan), Mitsubishi Tanabe Pharma (Osaka, Japan), Mochida Pharmaceutical (Tokyo, Japan), MSD (Tokyo, Japan), Nippon Boehringer Ingelheim (Tokyo, Japan), Otsuka Pharmaceutical (Tokyo, Japan), Shionogi (Osaka, Japan) and Takeda Pharmaceutical (Osaka, Japan). H.S. has received lecture fees from Bayer Yakuhin (Osaka, Japan), Daiichi Sankyo (Tokyo, Japan) and Novartis Pharma (Tokyo, Japan). NT-proBNP levels were measured at Roche Diagnostics K.K. (Tokyo, Japan).? Acknowledgement of grant support: The CHART-2 Study is supported in part by the Grants-in Aid from the Japanese Ministry of Health, Labour and Welfare and the Japanese Ministry of Education, Culture, Sports, Science and Technology and the Japan Agency for Medical Research and Development (15ek0210043h0001 16ek0210056h0001 16ek0210043h0002), Tokyo, Japan. The TOPCAT trial is supported by a contract from the National Heart, Lung, and Blood Institute, National Institutes of Health (HHSN268200425207C). The Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) study is supported by grants from National Medical Research Council of Singapore, Agency for Science, Technology and Research Biomedical Research Council Asian Network for Translational Research and Cardiovascular Trials program, Boston Scientific Investigator Sponsored Research Program, and Bayer.
Funding Information:
Acknowledgement of grant support: The CHART-2 Study is supported in part by the Grants-in Aid from the Japanese Ministry of Health, Labour and Welfare and the Japanese Ministry of Education, Culture, Sports, Science and Technology and the Japan Agency for Medical Research and Development ( 15ek0210043h0001 , 16ek0210056h0001 , 16ek0210043h0002 ), Tokyo, Japan.
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Background: Few simple risk models, without echocardiography have been developed for patients with heart failure (HF) and preserved left ventricular ejection fraction (LVEF) (HFpEF). Methods: To develop a risk score to predict all-cause death for HFpEF patients, we examined 1277 HF patients with LVEF ≥50% and BNP ≥100 pg/ml in the CHART-2 Study, a large-scale prospective cohort study for HF in Japan. We selected the optimal subset of covariates for the score with Cox proportional hazard models and random survival forests (RSF). Results: During the median 5.7-year follow-up, 576 deaths occurred. Cox models and RSF analyses consistently indicated age ≥75 years, albumin <3.7 g/dl, anemia, BMI <22 kg/m 2 , BNP ≥300 pg/ml (or NT-proBNP ≥1400 pg/ml), and BUN ≥25 mg/dl, as the important 6 prognostic variables. Incorporating these 6 variables, we developed a scoring system (3A3B score, with 2 points given to age ≥75 years and 1 point to the others based on the hazard ratios. The discrimination ability of the risk score was excellent (c-index 0.708). Regarding model goodness-of-fit, the overall gradient in 5-year risk was well captured by the score. The predictive accuracy of the 3A3B score was confirmed in the external validation cohorts from the TOPCAT trial (N = 835, c-index 0.652) and the ASIAN-HF registry (N = 170, c-index 0.741). Conclusions: We developed a simple risk score to predict long-term prognosis of HFpEF patients. The 3A3B score, comprising 6 commonly available parameters in daily practice, has potential utility in the risk stratification and management of HFpEF patients.
AB - Background: Few simple risk models, without echocardiography have been developed for patients with heart failure (HF) and preserved left ventricular ejection fraction (LVEF) (HFpEF). Methods: To develop a risk score to predict all-cause death for HFpEF patients, we examined 1277 HF patients with LVEF ≥50% and BNP ≥100 pg/ml in the CHART-2 Study, a large-scale prospective cohort study for HF in Japan. We selected the optimal subset of covariates for the score with Cox proportional hazard models and random survival forests (RSF). Results: During the median 5.7-year follow-up, 576 deaths occurred. Cox models and RSF analyses consistently indicated age ≥75 years, albumin <3.7 g/dl, anemia, BMI <22 kg/m 2 , BNP ≥300 pg/ml (or NT-proBNP ≥1400 pg/ml), and BUN ≥25 mg/dl, as the important 6 prognostic variables. Incorporating these 6 variables, we developed a scoring system (3A3B score, with 2 points given to age ≥75 years and 1 point to the others based on the hazard ratios. The discrimination ability of the risk score was excellent (c-index 0.708). Regarding model goodness-of-fit, the overall gradient in 5-year risk was well captured by the score. The predictive accuracy of the 3A3B score was confirmed in the external validation cohorts from the TOPCAT trial (N = 835, c-index 0.652) and the ASIAN-HF registry (N = 170, c-index 0.741). Conclusions: We developed a simple risk score to predict long-term prognosis of HFpEF patients. The 3A3B score, comprising 6 commonly available parameters in daily practice, has potential utility in the risk stratification and management of HFpEF patients.
KW - Heart failure
KW - HFpEF
KW - Left ventricular ejection fraction
KW - Prognosis
KW - Risk score
UR - http://www.scopus.com/inward/record.url?scp=85055987730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055987730&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2018.10.076
DO - 10.1016/j.ijcard.2018.10.076
M3 - Article
C2 - 30413304
AN - SCOPUS:85055987730
SN - 0167-5273
VL - 284
SP - 42
EP - 49
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -